Share Search
Visit the Share Search
Bioventix full-year revenue and profits improve
21st Oct 2019 11:33
(Sharecast News) - Bioventix, which specialises in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, reported a 6% improvement in revenue for the year on Monday, to £9.3m.
The AIM-traded firm said its profit before tax rose 1% in the year ended 30 June to £7m, while its cash fell £0.5m to £6.5m.
Its board declared a second interim dividend of 43p per share, up from 36p in the prior year, and a special dividend of 47p per share, down from 55p year-on-year.
"Looking ahead to the future, we keenly anticipate the roll-out of high sensitivity troponin assays and modest growth from additional vitamin D and other antibody sales and royalties," said the Bioventix board in its statement.
"Beyond that, growth will be linked not only to the troponin project but also our continued research activities as we look to seed additional projects that will germinate in the period 2025-2030 to create additional shareholder value."
As at 1113 BST, shares in Bioventix were down 4.24% at 3,409p.
The AIM-traded firm said its profit before tax rose 1% in the year ended 30 June to £7m, while its cash fell £0.5m to £6.5m.
Its board declared a second interim dividend of 43p per share, up from 36p in the prior year, and a special dividend of 47p per share, down from 55p year-on-year.
"Looking ahead to the future, we keenly anticipate the roll-out of high sensitivity troponin assays and modest growth from additional vitamin D and other antibody sales and royalties," said the Bioventix board in its statement.
"Beyond that, growth will be linked not only to the troponin project but also our continued research activities as we look to seed additional projects that will germinate in the period 2025-2030 to create additional shareholder value."
As at 1113 BST, shares in Bioventix were down 4.24% at 3,409p.